Evidence map›Paper›PMID 35230655›Full record

ArticleInfection2022

Molecular SARS-CoV-2 surveillance in Bavaria shows no Omicron transmission before the end of November 2021.

Jennifer Flechsler, Ute Eberle, Alexandra Dangel, Sabrina Hepner, Clara Wimmer, Johannes Lutmayr, Regina Konrad, Carola Berger, Laura Weise, Annika Sprenger and 11 more

Abstract read
In one paragraph

Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jennifer Flechsler *Department of Public Health Microbiology, Bavarian Health and Food Safety Authority (LGL), Veterinärstraße 2, 85764, Oberschleißheim, Germany.
Ute Eberle *Unit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Alexandra Dangel *NGS Core Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Sabrina HepnerNGS Core Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Clara WimmerUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Johannes LutmayrUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Regina KonradDepartment of Public Health Microbiology, Bavarian Health and Food Safety Authority (LGL), Veterinärstraße 2, 85764, Oberschleißheim, Germany.
Carola BergerNGS Core Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Laura WeiseNGS Core Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Annika SprengerNGS Core Unit, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Jörg ZeitlerUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Natali ParavinjaUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Hildegard AngermeierUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
George GithureUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Sandra SchmidtUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Bianca TreisUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Mercy OkeyoUnit of Virology, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Bernhard LieblState Institute of Health, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.
Nikolaus Ackermann *Department of Public Health Microbiology, Bavarian Health and Food Safety Authority (LGL), Veterinärstraße 2, 85764, Oberschleißheim, Germany.
Andreas Sing *Department of Public Health Microbiology, Bavarian Health and Food Safety Authority (LGL), Veterinärstraße 2, 85764, Oberschleißheim, Germany. andreas.sing@lgl.bayern.de.
Bavarian SARS-CoV-Public Health Laboratory Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFive SARS-CoV-2 variants are currently considered as variants of concern (VOC). Omicron was declared a VOC at the end of November 2021. Based on different diagnostic methods, the occurrence of Omicron was reported by 52 countries worldwide on December 7 2021. First notified by South Africa with alarming reports on increasing infection rates, this new variant was soon suspected to replace the currently pre-dominating Delta variant leading to further infection waves worldwide.

methodsUsing VOC PCR screening and Next Generation Sequencing (NGS) analysis of selected samples, we investigated the circulation of Omicron in the German federal state Bavaria. For this, we analyzed SARS-CoV-2 surveillance data from our laboratory generated from calendar week (CW) 01 to 49/2021.

resultsSo far, we have detected 69 Omicron cases in our laboratory from CW 47-49/2021 using RT-qPCR followed by melting curve analysis. The first 16 cases were analyzed by NGS and all were confirmed as Omicron.

conclusionOur data strongly support no circulation of the new Omicron variant before CW 47/2021.

Indexed as

COVID-19SARS-CoV-2High-Throughput Nucleotide SequencingHumansReal-Time Polymerase Chain ReactionCOVID-19OmicronSARS-CoV-2SurveillanceVariants of concern

Identifiers

PMID35230655
PMCPMC8886714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.